AMRI provides high-quality DMPK assays with capabilities that range from characterization of compound physicochemical properties through drug-drug interactions, bioanalytical/pharmacokinetic studies, and metabolite ID and synthesis. We conduct in vitro ADMET assays to evaluate and improve metabolism, bioavailability, pharmacology and toxicology of compounds.
AMRI’s ADMET service platform seamlessly integrates with our other discovery services to provide efficent and effective progression through the pipeline. The testing funnel below illustrates how our ADMET service platform seamlessly integrates with our other discovery services to provide efficent and effective progression through the pipeline.
AMRI provides the Life Sciences community with leading global, end-to-end contract research and manufacturing services. Locations on three continents provide targeted solutions to support the discovery, development and manufacturing of therapeutics.
AMRI now delivers a broader suite of capabilities across the drug discovery, development
and manufacturing spectrum. Our key business segments include:
We provide comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and sesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products.
AMRI supports the chemical development and cGMP manufacture of complex APIs, including potent and cytotoxic compounds, controlled substances, steroids, hormones and sterile APIs.
We support development through commercial-scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations.